Drug Profile
AB 393
Alternative Names: AB-393Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Aparna Biosciences
- Class Antineoplastics; Gene therapies; MicroRNAs
- Mechanism of Action RNA interference; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in USA
- 21 Jul 2016 AB 393 is available for licensing as of 21 Jul 2016. http://www.aparnabio.com/
- 21 Jul 2016 Preclinical trials in Cancer in USA (unspecified route)